As reported in an Morbidity and Mortality Weekly Report Early Release, Reference Dooling, Marin and Wallace1 demand for the coronavirus disease (COVID-19) vaccine was expected to exceed supply during the first months of the national COVID-19 vaccination program in the United States. Therefore, the Advisory Committee on Immunization Practices (ACIP) informed the Centers for Disease Control and Prevention (CDC) of population groups and circumstances for vaccine use. The CDC identified individuals in Phase 1a of vaccine distribution under Emergency Use Authorization (EUA) as mission-critical to ensure the continuity of critical functions in the United States. However, there were not enough doses for everyone in Phase 1a to receive vaccine on the first day of availability. Moreover, there was no guidance regarding how to prioritize health care workers (HCWs) within Phase 1a.
The National Academy of Medicine 2 recommended establishing tiers based on an individual’s work setting, responsibilities, and personal risks to promote equity and efficacy of allocation. To operationalize this guidance within an ethical framework, leaders at the University of Alabama at Birmingham (UAB) developed a sequencing schedule to attempt to capture HCWs’ potential for exposure to COVID-19 as well as their contribution to the essential mission of delivering health care during this unique public health emergency. Using the best available evidence, team leaders identified 7 categories of risk. These 7 criteria were rated on a 3-point scale (1 = low risk, 2 = medium risk, 3 = high risk) to calculate a composite score for each job classification. We illustrate priority ranking as well as criteria definitions in Figure 1.
The strategy of priority ranking provided a method of differentiating job classifications along a continuum, although the differences between categories were quite small. Nevertheless, composite scores provided a clear pathway for distributing vaccine doses as they arrived. In total, UAB Health System administered approximately 30 000 doses to HCWs during Phase 1a of the COVID-19 vaccine distribution under EUA. Emergency vaccine supply and distribution efficiency allowed all HCWs in Phase 1a who wanted vaccine to receive their first dose within the first 4 weeks of availability.
Looking Ahead
Results of a recent study indicated that the annual probability of extreme epidemics occurring could increase threefold in the coming decades. Reference Marani, Katul and Pan3 This projection of future infectious disease outbreaks may be attributed to global travel, increased antibiotic resistance, and vaccine hesitancy of common viruses based on attitudes toward the COVID-19 vaccine. Reference Parimi, Gilkeson and Creamer4 Based on the potential for future novel diseases, it is expected that forthcoming vaccines will be developed using mRNA technology, and mass vaccine distribution will once again be under a time constraint.
While each virus may behave differently, expert input can guide the unique criteria used to determine prioritization. Ultimately, the tool is limited as it requires subjective input by experts for each unique criterion and group; however, this method minimizes subjectivity and attempts to provide a level of objectivity to a process in which difficult decisions must be made under time constraints. We suggest that the prioritizing tool described in this article can be easily adapted for future disease outbreaks that require rapid deployment of limited resources to HCWs and others exposed to infections of unknown origin.
Competing interests
The authors have no conflicts of interest to report.